The global isocitrate dehydrogenase (IDH) inhibitors market garnered a market value of US$ 1.7 Billion in 2022 and is expected to accumulate a market value of US$ 39.16 Billion by registering a CAGR of 33% in the forecast period 2023 to 2033.
The market's growth can be attributed to the rising occurrence of IDH-mutated cancers, such as acute myeloid leukemia (AML) and cholangiocarcinoma, which are frequently managed using IDH inhibitors. The market for isocitrate dehydrogenase (IDH) inhibitors registered a CAGR of 18% in the historical period 2018 to 2022
Isocitrate dehydrogenase (IDH) inhibitors are a class of drugs that target the mutated form of the IDH enzyme found in certain types of cancer cells. These drugs work by blocking the activity of the mutated IDH enzyme, which is involved in the development and progression of cancer.
The IDH inhibitors market refers to the pharmaceutical industry's production and sale of these drugs. This market has grown significantly in recent years, with the approval of several IDH inhibitors by regulatory agencies such as the FDA and the EMA.
IDH inhibitors are primarily used in the treatment of acute myeloid leukemia (AML) and other types of cancers, such as cholangiocarcinoma and glioma, that have mutations in the IDH gene. The market for IDH inhibitors is expected to continue to grow as more research is conducted on the use of these drugs in the treatment of cancer.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 2.26 Billion |
| Anticipated Forecast Value (2033) | US$ 39.16 Billion |
| Projected Growth Rate (2023 to 2033) | 33% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Isocitrate dehydrogenase (IDH) inhibitors reflected a value of 18% during the historical period, 2018 to 2022.
The market is expected to be driven by several factors, including the growing incidence of cancer, the increasing adoption of personalized medicine, and the development of targeted therapies for cancer treatment. The availability of favorable regulatory frameworks for the approval of IDH inhibitors is also expected to drive growth in the market.
In terms of geography, North America has been the largest market for IDH inhibitors, followed by Europe and Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the growing prevalence of cancer in the region and increasing investment in healthcare infrastructure.
Overall, the IDH inhibitors market is expected to continue to grow over the forecast period, driven by increasing demand for more effective and targeted cancer treatments.
Thus, the market for Isocitrate dehydrogenase (IDH) inhibitors is expected to register a CAGR of 33% in the forecast period 2023 to 2033.
Increasing incidence of cancer driving the growth of IDH inhibitors market
The incidence of cancer is on the rise globally, and IDH inhibitors are a promising new class of drugs that offer targeted therapy for specific types of cancers. IDH mutations are found in a high percentage of certain types of cancers, such as AML, cholangiocarcinoma, and glioma. This provides a significant opportunity for the development and use of IDH inhibitors as a treatment option.
Advances in drug discovery and development techniques have enabled the identification and development of targeted therapies, such as IDH inhibitors, with greater efficacy and fewer side effects.
The regulatory environment for IDH inhibitors has been favorable, with several drugs already approved by regulatory agencies such as the FDA and EMA. This has encouraged investment in research and development of these drugs.
IDH inhibitors represent a targeted therapy that can be tailored to the specific genetic makeup of an individual's cancer. As demand for personalized medicine grows, the market for IDH inhibitors is likely to expand.
Development in inhibitors shaping the landscape for IDH inhibitors market
IDH1 inhibitors: These inhibitors specifically target the mutated form of the IDH1 enzyme, which is found in certain types of cancers such as cholangiocarcinoma and glioma. Examples of IDH1 inhibitors include ivosidenib (Tibsovo) and enasidenib (Idhifa), which have been approved by the FDA for the treatment of AML with IDH1 mutations.
IDH2 inhibitors: These inhibitors specifically target the mutated form of the IDH2 enzyme, which is found in certain types of cancers such as AML. Examples of IDH2 inhibitors include agios (AG-221), ivosidenib (Tibsovo), and enasidenib (Idhifa), which have been approved by the FDA for the treatment of AML with IDH2 mutations.
Principal Consultant
Limited patient population along with high drug development costs derailing market growth
IDH inhibitors are only effective in patients with specific genetic mutations in the IDH gene, which limits the eligible patient population for these drugs. This means that the market potential for IDH inhibitors is relatively small compared to other cancer therapies.
Developing targeted therapies such as IDH inhibitors can be expensive, and the costs associated with research and development may be passed on to consumers in the form of high drug prices. The market for cancer therapies is highly competitive, and there are several established treatments available for many types of cancers. IDH inhibitors face competition from other targeted therapies as well as traditional chemotherapy and radiation treatments.
Patients may develop resistance to IDH inhibitors over time, which can limit the effectiveness of these drugs in the long term. Like all drugs, IDH inhibitors can cause adverse effects, and patients may experience side effects such as nausea, vomiting, and fatigue. Managing these side effects can be challenging for both patients and healthcare providers. All these factors are hampering the market growth of IDH inhibitors market.
Presence of key market players bolstering the market growth for IDH inhibitors market in North America
The North America Isocitrate Dehydrogenase (IDH) inhibitors market is one of the largest markets for these drugs globally. The market is primarily driven by the high prevalence of cancer in the region and the increasing use of targeted therapies for cancer treatment.
In North America, the United States is the largest market for IDH inhibitors, followed by Canada. The FDA has approved several IDH inhibitors for the treatment of AML and other types of cancers, which has contributed to the growth of the market.
Moreover, the presence of key players in the region, such as Agios Pharmaceuticals, Celgene Corporation, and Daiichi Sankyo, has also fueled the growth of the market. These companies have invested heavily in research and development to bring new IDH inhibitors to the market. Thus, North America is expected to possess 46% market share for IDH inhibitors market in 2023.
Growing incidence of cancer in Europe boosting market growth of ISH inhibitors
The incidence of cancer is on the rise in Europe, and this is driving demand for more effective cancer treatments such as IDH inhibitors. Pharmaceutical companies are investing heavily in research and development of IDH inhibitors to develop more effective and targeted therapies for cancer treatment.
The European Medicines Agency (EMA) has granted accelerated approval to several IDH inhibitors, which has created a favorable regulatory environment for the development and commercialization of these drugs.
IDH inhibitors are a type of personalized medicine that targets specific mutations in cancer cells, and as awareness about personalized medicine grows, demand for IDH inhibitors is also increasing.
There is a strong pipeline of IDH inhibitors in Europe, with several drugs in various stages of clinical trials. This is expected to drive growth in the market in the coming years. Thus, Europe is expected to possess 43% market share for IDH inhibitors market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Fewer side effects of oral IDH inhibitors making them easier for consumption
By route of administration, the IDH inhibitors market is segmented into Oral, Parenteral and Subcutaneous
Oral Isocitrate Dehydrogenase (IDH) inhibitors are one of the types of IDH inhibitors used in cancer therapy. Oral IDH inhibitors have certain advantages over other types of cancer therapies, such as chemotherapy, which is typically administered intravenously. Oral medications can be taken at home, and they may have fewer side effects than chemotherapy. Additionally, oral IDH inhibitors are often more targeted and may be more effective against cancer cells with specific IDH mutations.
Thus, by route of administration, oral IDH inhibitors is expected to possess 49% market share for IDH inhibitors market in 2023.
Key players in the isocitrate dehydrogenase (IDH) inhibitors market are Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 2.26 Billion |
| Market Value in 2033 | US$ 39.16 Billion |
| Growth Rate | CAGR of 33% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The global market is worth US$ 2.26 billion in 2023.
The market is anticipated to thrive at a 33% CAGR from 2023 to 2033.
The market expanded at an 18% CAGR from 2018 to 2022.
Europe’s holds nearly 43% of the market share in 2023.
The oral IDH inhibitors segment leads, with 49% of the market share in 2023.
1. Executive Summary | Isocitrate Dehydrogenase (IDH) Inhibitors Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. IDH1 Mutant Medullary Malignant Tumor
5.3.2. IDH2 Mutant Medullary Malignant Tumor
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, ByMolecule Types
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis ByMolecule Types, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast ByMolecule Types, 2023 to 2033
6.3.1. Monoclonal Antibody
6.3.2. Peptides
6.3.3. Small molecule
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis ByMolecule Types, 2018 to 2022
6.5. Absolute $ Opportunity Analysis ByMolecule Types, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Subcutaneous
7.3.4. Topical
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Type
9.2.3. ByMolecule Types
9.2.4. By Route of Administration
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. ByMolecule Types
9.3.4. By Route of Administration
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. ByMolecule Types
10.2.4. By Route of Administration
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. ByMolecule Types
10.3.4. By Route of Administration
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Type
11.2.3. ByMolecule Types
11.2.4. By Route of Administration
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. ByMolecule Types
11.3.4. By Route of Administration
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Type
12.2.3. ByMolecule Types
12.2.4. By Route of Administration
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. ByMolecule Types
12.3.4. By Route of Administration
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Type
13.2.3. ByMolecule Types
13.2.4. By Route of Administration
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. ByMolecule Types
13.3.4. By Route of Administration
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Type
14.2.3. ByMolecule Types
14.2.4. By Route of Administration
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. ByMolecule Types
14.3.4. By Route of Administration
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Type
15.2.3. ByMolecule Types
15.2.4. By Route of Administration
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Type
15.3.3. ByMolecule Types
15.3.4. By Route of Administration
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Type
16.1.2.2. ByMolecule Types
16.1.2.3. By Route of Administration
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Type
16.2.2.2. ByMolecule Types
16.2.2.3. By Route of Administration
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Type
16.3.2.2. ByMolecule Types
16.3.2.3. By Route of Administration
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Type
16.4.2.2. ByMolecule Types
16.4.2.3. By Route of Administration
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Type
16.5.2.2. ByMolecule Types
16.5.2.3. By Route of Administration
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Type
16.6.2.2. ByMolecule Types
16.6.2.3. By Route of Administration
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Type
16.7.2.2. ByMolecule Types
16.7.2.3. By Route of Administration
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Type
16.8.2.2. ByMolecule Types
16.8.2.3. By Route of Administration
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Type
16.9.2.2. ByMolecule Types
16.9.2.3. By Route of Administration
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Type
16.10.2.2. ByMolecule Types
16.10.2.3. By Route of Administration
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Type
16.11.2.2. ByMolecule Types
16.11.2.3. By Route of Administration
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Type
16.12.2.2. ByMolecule Types
16.12.2.3. By Route of Administration
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Type
16.13.2.2. ByMolecule Types
16.13.2.3. By Route of Administration
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Type
16.14.2.2. ByMolecule Types
16.14.2.3. By Route of Administration
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Type
16.15.2.2. ByMolecule Types
16.15.2.3. By Route of Administration
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Type
16.16.2.2. ByMolecule Types
16.16.2.3. By Route of Administration
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Type
16.17.2.2. ByMolecule Types
16.17.2.3. By Route of Administration
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Type
16.18.2.2. ByMolecule Types
16.18.2.3. By Route of Administration
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Type
16.19.2.2. ByMolecule Types
16.19.2.3. By Route of Administration
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Type
16.20.2.2. ByMolecule Types
16.20.2.3. By Route of Administration
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Type
16.21.2.2. ByMolecule Types
16.21.2.3. By Route of Administration
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Type
17.3.3. By Molecule Types
17.3.4. By Route of Administration
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Bayer
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Agios Pharma
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Daiichi Sankyo
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Ohm Oncology
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Celgene
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Philogen S.p.A.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Tragara
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Aslan Pharmaceuticals
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Pfizer, Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Sun Pharmaceutical Industries Ltd.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Isocitrate Dehydrogenase (IDH) Inhibitors Market
